Global Tumor-Specific Antigen Market

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives


• Reasons for Doing This Study


• Scope of Report


• Information Sources


• Methodology


• Geographic Breakdown


• Analyst’s Credentials


• Custom Research


• Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

• Market Overview


• Market Potential


• Investment Analysis


• Regulatory Framework


• United States


• European Union


• Australia


• Japan


• India


• China


• Industry Growth Drivers


• Surging Demand for Potential Cancer Biomarker Candidates


• Rising Prevalence of Cancer


• Increasing Investments in Cancer Diagnosis and Research


• Rising Focus on Developing Targeted Therapies


• Antigen Specific T-Cell Therapy

Chapter 4 Tumor-specific Antigen Market by Category

• Oncofetal


• Oncoviral


• Overexpressed/Accumulated


• CT9/CT10


• Mutated


• Lineage-Restricted Antigen


• Idiotypic


• Others

Chapter 5 Tumor-specific Antigen Market by Source

• Coding Region


• Non-Coding Region


• Growing the Background of Immunotherapy Targets

Chapter 6 Tumor-specific Antigen Market by Application

• Diagnostics


• Drug Discovery and Development


• Therapeutics


• Risk Assessment


• Prognostics


• Clinical and Basic Research

Chapter 7 Tumor-specific Antigen Market by Region

• North America


• United States


• Canada


• Europe


• United Kingdom


• France


• Germany


• Spain


• Rest of Europe


• Asia-Pacific


• China


• India


• Japan


• Australia


• Rest of Asia-Pacific


• Rest of the World


• Latin America


• Middle East and Africa

Chapter 8 Tumor-specific Antigen Market Industry Structure

• Industry Structure


• Procurement of Raw Materials


• Manufacturing/Development Process


• End-Users


• Innovation in the Market


• Competitive Analysis

Chapter 9 Company Profiles

• ABCAM PLC


• AGILENT TECHNOLOGIES INC.


• AIVITA BIOMEDICAL


• BBI GROUP


• BIOMÉRIEUX SA


• BIO-RAD LABORATORIES INC.


• BRIGHTPATH BIOTHERAPEUTICS


• CARIS LIFE SCIENCES INC.


• CISBIO BIOASSAYS


• CREATIVE DIAGNOSTICS


• ELI LILLY AND CO.


• ENZO BIOCHEM INC.


• EXTERNAUTICS


• F. HOFFMANN-LA ROCHE LTD.


• GO THERAPEUTICS


• JANSSEN GLOBAL SERVICES LLC


• LEE BIOSOLUTIONS INC.


• MERCK MILLIPORE


• MESO SCALE DIAGNOSTICS, LLC


• PERKINELMER INC.


• QUEST DIAGNOSTICS


• SIGNOSIS INC.

List of Tables
Summary Table: Global Market for Tumor-specific Antigen, by Source, Through 2023
Table 1: Investment Analysis
Table 2: Biomarkers for Cancer Detection, Diagnosis and Prognosis
Table 3: Protein Arrays: Cancer Biomarker Discovery
Table 4: Global Prevalence of Cancer, by Type, 2016
Table 5: Regional Cancer Prevalence, by Type, 2015 and 2016
Table 6: Investment in Cancer, by Area of Research, 2017
Table 7: Investments in Cancer-Based Research, 2016-2018
Table 8: Molecular Targeted Therapy in Anticancer
Table 9: CAR Target Antigen for Hematologic Malignancies and Potential Off-Tumor Targets
Table 10: Global Market for Tumor-specific Antigen, by Category, Through 2023
Table 11: Tumor Antigen
Table 12: Global Market for Oncofetal Antigen, by Region, Through 2023
Table 13: Pharmaceutical and Bioinformatic Partnerships and Alliances
Table 14: Global Market for Oncoviral Antigen, by Region, Through 2023
Table 15: U.S. R&D Funding for Basic Research
Table 16: Global Market for Overexpressed/Accumulated Antigen, by Region, Through 2023
Table 17: Investment in Cancer, by Research Area
Table 18: Global Market for CT9/CT10 Antigen, by Region, Through 2023
Table 19: Regional Cancer Prevalence, by Type, 2015 and 2016
Table 20: Global Market for Mutated Antigen, by Region, Through 2023
Table 21: Global Leukemia Deaths, 2016
Table 22: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
Table 23: Global Market for Lineage Restricted Antigen, by Region, Through 2023
Table 24: Global Cancer Prevalence and Mortality Rate, 2012 and 2030
Table 25: Global Prevalence of Cancer, by Type, 2016
Table 26: Global Cancer Mortalities, by Type, 2016
Table 27: Global Market for Idiotypic-Based Antigen, by Region, Through 2023
Table 28: Clinical Trials in Idiotypic
Table 29: Identified Post-Translationally Modified AutoAntigen
Table 30: Global Market for Other Antigen, by Region, Through 2023
Table 31: Global Prevalence of Diabetes, 2017 and 2045
Table 32: Global Market for Tumor-specific Antigen, by Source, Through 2023
Table 33: Tumor and Tissue-Specific Promoters Used to Generate Tumor-specific Antigen Sourced Through Coding Region
Table 34: Global Market for Coding Region-Based Antigen, by Region, Through 2023
Table 35: Global Market for Non-Coding Region-Based Antigen, by Region, Through 2023
Table 36: Global Market for Tumor-specific Antigen, by Application, Through 2023
Table 37: Key Immunological Techniques for Diagnosis of Cancer
Table 38: Global Market for Tumor-specific Antigen in Diagnostic Applications, by Region, Through 2023
Table 39: Circulating Antigen and Immunodiagnosis of Cancer
Table 40: Global Market for Tumor-specific Antigen in Drug Discovery and Development Applications, by Region, Through 2023
Table 41: Clinical Trials Involving Tumor-specific Antigen for Cancer Therapeutics
Table 42: Global Market for Tumor-specific Antigen in Therapeutic Applications, by Region, Through 2023
Table 43: Global Market for Tumor-specific Antigen in Risk Assessment Applications, by Region, Through 2023
Table 44: Global Market for Tumor-specific Antigen in Prognostic Applications, by Region, Through 2023
Table 45: Global Prevalence of Different Cancers, by Country, 2016
Table 46: Deaths from Different Cancer Type, by Country, 2016
Table 47: NCI Funding, 2012-2017
Table 48: Global Market for Tumor-specific Antigen in Clinical and Basic Research Applications, by Region, Through 2023
Table 49: North American Market for Tumor-specific Antigen, by Country, Through 2023
Table 50: North American Market for Tumor-specific Antigen, by Category, Through 2023
Table 51: U.S. Funding for Cancer Research, by Type, 2015 and 2016
Table 52: North American Market for Tumor-specific Antigen, by Source, Through 2023
Table 53: U.S. Market for Tumor-specific Antigen, by Source, Through 2023
Table 54: Canadian Market for Tumor-specific Antigen, by Source, Through 2023
Table 55: North American Market for Tumor-specific Antigen, by Application, Through 2023
Table 56: European Market for Tumor-specific Antigen, by Country/Region, Through 2023
Table 57: European Market for Tumor-specific Antigen, by Category, Through 2023
Table 58: Cancer Prevalence in the U.K., by Country, 2015 and 2020
Table 59: European Market for Tumor-specific Antigen, by Source, Through 2023
Table 60: U.K. Market for Tumor-specific Antigen, by Source, Through 2023
Table 61: Funding for Biology and Basic Sciences for Cancer Research in France, 2007-2015
Table 62: French Market for Tumor-specific Antigen, by Source, Through 2023
Table 63: German Market for Tumor-specific Antigen, by Source, Through 2023
Table 64: Ongoing Cancer-Based Trials in Germany
Table 65: Cancer Cases in Spain, 2012 and 2015
Table 66: European Market for Tumor-specific Antigen, by Application, Through 2023
Table 67: Spanish Market for Tumor-specific Antigen, by Source, Through 2023
Table 68: Projects Recommended to the NCU Board for Funding, 2016
Table 69: Rest of European Market for Tumor-specific Antigen, by Source, Through 2023
Table 70: Asia-Pacific Market for Tumor-specific Antigen, by Country/Region, Through 2023
Table 71: Asia-Pacific Market for Tumor-specific Antigen, by Source, Through 2023
Table 72: Cancer Incidence in China, 2016
Table 73: Asia-Pacific Market for Tumor-specific Antigen, by Category, Through 2023
Table 74: Chinese Market for Tumor-specific Antigen, by Source, Through 2023
Table 75: Clinical Trials for Cancer
Table 76: Indian Market for Tumor-specific Antigen, by Source, Through 2023
Table 77: Asia-Pacific Market for Tumor-specific Antigen, by Application, Through 2023
Table 78: Japanese Market for Tumor-specific Antigen, by Source, Through 2023
Table 79: Australian Market for Tumor-specific Antigen, by Source, Through 2023
Table 80: Change in Cancer Prevalence in Other APAC Countries, 2005-2016
Table 81: Rest of APAC Market for Tumor-specific Antigen, by Source, Through 2023
Table 82: Clinical Trials for Tumor-specific Antigen: Singapore
Table 83: RoW Market for Tumor-specific Antigen, by Region, Through 2023
Table 84: Cancer Incidence in Brazil, 2016
Table 85: Latin American Market for Tumor-specific Antigen, by Source, Through 2023
Table 86: RoW Market for Tumor-specific Antigen, by Category, Through 2023
Table 87: Causes of Death in Argentina and Percentage Change, 2005-2016
Table 88: RoW Market for Tumor-specific Antigen, by Source, Through 2023
Table 89: RoW Market for Tumor-specific Antigen, by Application, Through 2023
Table 90: Cancer Prevalence in Kenya, by Type, 2015 and 2016
Table 91: Middle Eastern and African Market for Tumor-specific Antigen, by Source, Through 2023
Table 92: Global Suppliers of Tumor-specific Antigen Market
Table 93: Selected Tumor-specific Antigen Companies
Table 94: Cancer Antigen for Clinical Trials, as of January 2019
Table 95: Product Launches, Product Development and FDA Clearance
Table 96: Notable Mergers and Acquisitions
Table 97: Notable Agreements, Collaborations and Partnerships
Table 98: Notable Funding, Expansion and Divestment
Table 99: Abcam PLC: Product Portfolio
Table 100: Abcam PLC: Recent Developments
Table 101: Agilent Technologies Inc.: Product Portfolio
Table 102: Agilent Technologies Inc.: Recent Developments
Table 103: AIVITA Biomedical: Product Portfolio
Table 104: AIVITA Biomedical: Recent Developments
Table 105: BBI Group: Product Portfolio
Table 106: Biomérieux SA: Product Portfolio
Table 107: Bio-Rad Laboratories Inc.: Product Portfolio
Table 108: Bio-Rad Laboratories Inc.: Recent Developments
Table 109: BrightPath Biotherapeutics: Product Portfolio
Table 110: BrightPath Biotherapeutics: Recent Developments
Table 111: Caris Life Sciences Inc.: Product Portfolio
Table 112: Caris Life Sciences Inc.: Recent Developments
Table 113: Cisbio Bioassays: Product Portfolio
Table 114: Creative Diagnostics: Product Portfolio
Table 115: Creative Diagnostics: Recent Developments
Table 116: Eli Lilly and Co.: Product Portfolio
Table 117: Eli Lilly and Co.: Recent Developments
Table 118: Enzo Biochem Inc.: Product Portfolio
Table 119: Enzo Biochem Inc.: Recent Developments
Table 120: Externautics: Product Portfolio
Table 121: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 122: F. Hoffmann-La Roche Ltd.: Recent Developments
Table 123: GO Therapeutics: Product Portfolio
Table 124: GO Therapeutics: Recent Developments
Table 125: Janssen Global Services LLC: Product Portfolio
Table 126: Janssen Global Services LLC: Recent Developments
Table 127: Lee Biosolutions Inc.: Product Portfolio
Table 128: Merck Millipore: Product Portfolio
Table 129: Merck Millipore: Recent Developments
Table 130: Meso Scale Diagnostics, LLC: Product Portfolio
Table 131: Meso Scale Diagnostics, LLC: Recent Developments
Table 132: PerkinElmer Inc.: Product Portfolio
Table 133: PerkinElmer Inc.: Recent Developments
Table 134: Quest Diagnostics: Product Portfolio
Table 135: Quest Diagnostics: Recent Developments
Table 136: Signosis Inc.: Product Portfolio

List of Figures
Summary Figure: Global Market for Tumor-specific Antigen, by Source, 2017-2023
Figure 1: Regional Prevalence of Cancer, 2015-2016
Figure 2: Global Prevalence of Cancer, by Type, 2016
Figure 3: Targeting of Tumor-specific Mutated Antigen in T-Cell Immunotherapy
Figure 4: Global Leukemia Deaths, 2016
Figure 5: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
Figure 6: Global Cancer Prevalence and Mortality Rate, 2012 and 2030
Figure 7: Global Prevalence of Cancer, by Type, 2016
Figure 8: Global Cancer Mortalities, by Type, 2016
Figure 9: Determination of Antibody Idiotype
Figure 10: Global Prevalence of Diabetes, 2017 and 2045
Figure 11: Sources of Tumor-specific Antigen
Figure 12: Key Applications: Tumor-specific Antigen
Figure 13: Drug Discovery Cycle
Figure 14: Clinical Cancer Research for Therapeutic Applications
Figure 15: The Role of Prognostic and Predictive Markers in Individualized Treatment
Figure 16: Global Prevalence of Different Cancers, by Country, 2016
Figure 17: Deaths from Different Cancer Type, by Country, 2016
Figure 18: NCI Funding, 2012-2017
Figure 19: Funding for Biology and Basic Sciences for Cancer Research in France, 2007-2015
Figure 20: Cancer Incidence in China, 2016
Figure 21: Major Breakthroughs in Cancer Research: India
Figure 22: Cancer Prevalence in Kenya, by Type, 2015 and 2016
Figure 23: Tumor-specific Antigen Industry Structure
Figure 24: Tumor-specific Antigen Development Flow Chart

Companies Mentioned

• ABCAM PLC


• AGILENT TECHNOLOGIES INC.


• AIVITA BIOMEDICAL


• BBI GROUP


• BIO-RAD LABORATORIES INC.


• BIOMÉRIEUX SA


• BRIGHTPATH BIOTHERAPEUTICS


• CARIS LIFE SCIENCES INC.


• CISBIO BIOASSAYS


• CREATIVE DIAGNOSTICS


• ELI LILLY AND CO.


• ENZO BIOCHEM INC.


• EXTERNAUTICS


• F. HOFFMANN-LA ROCHE LTD.


• GO THERAPEUTICS


• Janssen Global Services Llc


• LEE BIOSOLUTIONS INC.


• MERCK MILLIPORE


• MESO SCALE DIAGNOSTICS, LLC


• PERKINELMER INC.


• QUEST DIAGNOSTICS


• SIGNOSIS INC.